In many occasions, Clay Siegall has been called a savior to cancer patients and their family. In the last few decades, scientists have worked hard to ensure that cancer patients can live longer and enjoy better lives. By founding Seattle Genetics, he has managed to make this dream a reality. Unlike traditional cancer-therapy research institutions, the facility focuses on developing cancer treatments that use special proteins to target and kill cancer cells without affecting healthy cells.
Dr. Siegall’s interest in how organisms work started at an early age. He joined the University of Maryland to learn more by pursuing a bachelor’s degree in zoology. He furthered his education and later earned his doctorate in Genetics from George Washington University. Exposure has given him the ability to understand how cancer cells works and what is required to kill them effectively.
By working with cancer research institutions, Dr. Clay Siegall has been able to gain the necessary experience in the field. He started his career at the National Institute of Health before joining National Cancer Institute. His desire to learn more and experience how other institutions were approaching cancer research saw him join Bristol-Myers Squibb Pharmaceutical Research Institute. Later, Siegall founded Seattle Genetics. The company has helped to fill the gap in oncology by making key improvements in the field. He is also associated with other cancer therapy developing companies such as Mirna, Alder Pharmaceuticals, and Ultragenyx Pharmaceutical.
For Siegall, sharing knowledge helps to enlighten the public about the ongoing research. He has continued to publish his findings on cancer treatment. Currently, he has 70 publications. However, to ensure that other businesses do not steal his ideas, he has patented his ideas.
The first cancer therapy that was developed by his company is Adcetris (Brentuximab Vedotin). Soon after its release, the FDA approved the drug. This is after proving that it was managing different forms of cancer that were previously untreated. The drug has also proved to be effective against the newly diagnosed Hodgkin lymphoma. Sale of the drug has seen the revenues of the company improve, as it no longer needs to rely on funding from investors to fund its research and pay for its recurring expenses.